Cell Metabolism:炎症、肥胖和胰岛素抵抗间关联新信号NBR1/MEKK3

2014-07-21 王英 生物通

肥胖(obesity)是目前全球多发病之一,常并发2型糖尿病。大量的研究表明,肥胖(尤其是内脏型肥胖)是产生胰岛素抵抗(insulin resistance)的重要因素,而胰岛素抵抗又是2型糖尿病发生的基础。 最近,由美国桑德福伯翰医学研究所(Sanford-Burnham)的研究人员进行的一项新研究,发现了一种新的信号,可触发一连串事件,引起肥胖所致的胰岛素抵抗。

肥胖(obesity)是目前全球多发病之一,常并发2型糖尿病。大量的研究表明,肥胖(尤其是内脏型肥胖)是产生胰岛素抵抗(insulin resistance)的重要因素,而胰岛素抵抗又是2型糖尿病发生的基础。

最近,由美国桑德福伯翰医学研究所(Sanford-Burnham)的研究人员进行的一项新研究,发现了一种新的信号,可触发一连串事件,引起肥胖所致的胰岛素抵抗。

这个信号可引起脂肪组织炎症,并导致代谢性疾病。相关研究结果于2014年7月17日发表在国际代谢研究领域顶尖杂志《细胞代谢》(Cell Metabolism),表明阻断该信号可预防代谢性疾病、2型糖尿病和其他肥胖相关炎症所致疾病的发展。

Sanford-Burnham细胞死亡和生存网络计划主任Jorge Moscat教授指出:“我们发现了一种精确的机制,可解释炎症如何发生在肥 胖症中。”本研究联合主任Maria Diaz-Meco博士表示:“这些结果很重要,因为我们知道,脂肪组织炎症可导致胰岛素抵抗,胰岛素抵抗是代谢综合征的一个风险因素和2型糖尿病的一个主要特征。如果我们能够抑制肥胖相关的炎症,我们也许就能够防止肥胖相关的代谢异常,包括2型糖尿病。”

NBR1蛋白可触发炎症

在本研究中,研究人员将具有各种不同身体质量指数(BMI)和肥胖度的健康男性和女性的NBR1蛋白质水平,与患有代谢综合征男性的NBR1蛋白质水 平进行比较。NBR1一种炎症性信号分子,最初发现于Moscat和Maria Diaz-Meco实验室。代谢综合征是各种健康问题(包括胰岛素抵抗) 组合的一种临床分类,与糖尿病和早期心脏病的风险增加有关。

分析发现,患有代谢综合征的男性具有较高水平的NBR1,与代谢改变和炎症标志物有关,从而提供了最初的线索表明,NBR1在肥胖相关的炎症和代谢综合征中发挥一定的作用。

NBR1如何发挥作用

为了了解NBR1如何发挥作用,研究小组用高脂饮食喂养NBR1灭活的小鼠。与正常小鼠相比,没有NBR1的小鼠具有更少的炎症和更好的葡萄糖耐受性,这表明该蛋白质可促进炎症和葡萄糖耐受不良。

研究人员继续指出,NBR1通过结合一个称为MEKK3的蛋白质,介导这种作用,当NBR1和MEKK3相互作用时,它们可以引起脂肪组织炎症。

Diaz-Meco称:“MEKK3是一种非常有吸引力的蛋白质,因为在临床上可以用一些小分子靶定它,而这些小分子可为胰岛素抵抗和2型糖尿病,带来新药物的开发。”

本文共同作者、佛罗里达州医院首席科学官、Sanford-Burnham代谢疾病项目教授Steven R. Smith博士补充说:“据估计,超过35%的美国成年人为胰岛素抵抗,而且没有干预,这些人之中很多人将发展成为2型糖尿病。下一步重要的是,寻找MEKK3-NBR1抑制剂,来逆转胰岛素抵抗,有望为2型糖尿病的治疗带来新疗法。”

原始出处:

Eloy D. Hernandez, Sang Jun Lee, Ji Young Kim, Angeles Duran, Juan F. Linares, Tomoko Yajima, Timo D. Müller, Matthias H. Tschöp, and others.A Macrophage NBR1-MEKK3 Complex Triggers JNK-Mediated Adipose Tissue Inflammation in Obesity.Cell Metabolism,Published online: July 17, 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
    2015-06-29 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
    2014-08-15 naiwu77
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
    2015-06-02 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
    2015-02-21 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
    2015-03-29 baoya
  7. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1895739, encodeId=6a0e1895e3984, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 29 19:22:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Aug 15 13:22:00 CST 2014, time=2014-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868860, encodeId=158c1868860f1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 08 11:22:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887395, encodeId=5e70188e395ba, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 02 06:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959105, encodeId=45b1195910509, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 21 18:22:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749491, encodeId=8ce51e49491e4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Mar 29 04:22:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577141, encodeId=0bd615e714100, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597920, encodeId=dfcf159e92057, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Jul 23 13:22:00 CST 2014, time=2014-07-23, status=1, ipAttribution=)]
    2014-07-23 闆锋旦

相关资讯

Rheumatology:超重的骨关节炎患者疼痛程度更严重

新近一项研究提示,具有膝关节炎的超重和肥胖人群感受到的疼痛程度可能大于关节损伤程度相同但体重较轻的患者。 既往研究已指出,体重较重的人群,尤其女性,发生骨关节炎的可能性更大,且发生更为严重的骨关节炎(OA)的可能性也更大。新近的这项研究在此基础上进行了更进一步的研究,结果提示,体重指数(BMI)较大的患者与关节相关损伤量相同的正常体重者相比,其疼痛程度更高。 来自美国加利福尼亚圣何塞州立大学的

Cell:阐述何谓“健康”的肥胖

当前有多达四分之一被打上肥胖标签的个体实际上新陈代谢健康,并没有罹患2型糖尿病的高风险。尽管肥胖是糖尿病的一个主要风险因子,这两种疾病也并不总是关联在一起。发表在7月3日《细胞》(Cell)杂志上的一项新研究提供了一个合理的解释,揭示出高水平的heme oxygenase-1 (HO-1)分子与肥胖人士代谢健康不佳以及2型糖尿病风险增高相关。并且,抑制HO-1可以改善肥胖小鼠的代谢健康,

Cell:过肥胖对北极熊而言是健康状态

5月9日,来自深圳华大基因研究院、美国加利福利亚大学、丹麦哥本哈根大学等单位的科学家们完整解读了北极熊基因组,揭示了北极熊适应北极极地气候之谜。最新成果以封面故事发表在《细胞》杂志上。研究人员通过对北极熊和棕熊进行比较基因组分析后,发现北极熊实际上比之前人们所认为的要更年轻,与它的近亲棕熊的分化时间只有不到50万年。通过对群体数据进行分析,研究人员推算出北极熊的群体大小在2万~2.5万之间,且处于

Cell Metabolism:阻断NBR1-MEKK3信号或可预防2型糖尿病

肥胖(obesity)是目前全球多发病之一,常并发2型糖尿病。大量的研究表明,肥胖(尤其是内脏型肥胖)是产生胰岛素抵抗(insulin resistance)的重要因素,而胰岛素抵抗又是2型糖尿病发生的基础。 最近,由美国桑德福伯翰医学研究所(Sanford-Burnham)的研究人员进行的一项新研究,发现了一种新的信号,可触发一连串事件,引起肥胖所致的胰岛素抵抗。 这个信号可引起脂

Pediatr Obes:BMI可漏诊超过25%脂肪超标的儿童

美国一项荟萃分析表明,体质指数(BMI)未能确认超过四分之一的体脂百分比超标儿童。论文于6月24日在线发表于《儿科肥胖症》(Pediatr Obes)。 研究者检索了相关数据库,并纳入了将BMI与测定过量体脂标准参照方法进行对比的研究。研究目标为评估BMI在儿童和青少年中检出肥胖的敏感性和特异性。 结果显示,共有包括53521例4~18岁儿童的37项研究符合纳入标准。常用B

Diabetes Care:肥胖标准需要区分不同民族

根据英国一项最新的研究显示,同样的糖尿病患病风险,黑人和亚洲成年人与白人相比可能体重更低。根据调查结果,研究人员建议:肥胖的定义应该针对不同人群制定不同标准,这样才能及时干预糖尿病的发生。美国疾控中心(CDC)对超重的定义是BMI指数 25-29.9,肥胖则为BMI指数>30。WHO专家已经认识到,这些指标主要适用于白人,只是很少有人注意到这点,WHO和CDC还没有根据种族特异性来制定超重和肥胖的